Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Core Laboratories N.V. (CLB)

$14.65
-2.65 (-15.32%)
Get curated updates for this stock by email. We filter for the most important fundamentals-focused developments and send only the key news to your inbox.

Data provided by IEX. Delayed 15 minutes.

Company Profile

Price Chart

Loading chart...

At a glance

Production Enhancement Margin Recovery Drives Earnings Power: CLB's Production Enhancement segment delivered an 82% operating income increase in 2025, with margins expanding from 3.7% to 6.7% despite flat revenue, demonstrating that operational leverage and mix shift toward high-margin diagnostic services are creating meaningful earnings leverage that could accelerate with any volume recovery.

Balance Sheet Transformation Enables Strategic Flexibility: Having reduced net debt by 70% since 2019 to its lowest level in eight years, CLB has pivoted from defensive deleveraging to opportunistic capital allocation, repurchasing shares for five consecutive quarters while maintaining a 1.09x leverage ratio, signaling management confidence and creating downside protection.

Proprietary Technology Moats Defend Niche Position: CLB's SPECTRISTIM tracers (endorsed by U.S. regulators), HERO PerFRAC perforating system, and award-winning Pulverizer plug-and-abandonment technology provide quantifiable cost advantages ($400,000+ per casing string) that differentiate it from larger, less specialized competitors and support pricing power in specialized applications.